Health
VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms – TCTMD
Whether the benefit-risk balance is favorable depends on many factors, but it will be so “in very many cases,” the researcher says.
Venous thromboembolic (VTE) events are indeed increased after people get the COVID-19 vaccine from Oxford/AstraZeneca, but the absolute risk is low considering the proven effectiveness of vaccination and the continued spread of SARS-CoV-2 around the globe, researchers report in the BMJ.
After vaccination programs got underway, spontaneous reports of thrombotic events in people who had received the vaccine started coming in, with several European countries pausing its use in March due to the clots….
-
Business22 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News21 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General16 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News18 hours agoTips to improve engagement – Proctor